Search

23 Feb 2024: models harboring distinct p53 deficiencies, namely complete loss of p53 (Null); mutations that cause loss of p53 contact with DNA and mutations that alter the correct conformation of the protein. ... of this therapeutic approach even when p53 mutations

1 Jun 2024: Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: The Y220X Paradigm. ... doi:A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C.

23 Feb 2024: For example, hPSCs recurrently acquire cancer-associated mutations in the tumour suppressor TP53 (p53) that promote growth in culture and would increase the risk of cancer formation from transplanted cells (Merkle ... Human pluripotent stem cells

23 Feb 2024: September 5, 2017. The KRAS oncogene is frequently activated by mutations in cancers (including 90% of pancreatic cancers and 30-40% of colorectal or lung cancers). ... Approximately half of lung adenocarcinomas, the most common type of lung cancer,

My later work in human pluripotent stem cell (hPSC) genomics provided open-access resources for rational cell line selection, revealed recurrent mutations in p53 that profoundly impacted the fields of stem ... Human pluripotent stem cells recurrently

23 Feb 2024: 2018) Epidermal Tissue Adapts to Restrain Progenitors Carrying Clonal p53 Mutations.

23 Feb 2024: For example, we recently showed that hPSCs recurrently acquire cancer-associated mutations in the tumour suppressor TP53 (p53) that promote growth in culture and would increase the risk of cancer formation ... novel methods to identify culture conditions

23 Feb 2024: RNA exosome mutations in pontocerebellar hypoplasia alter ribosome biogenesis and p53 levels. ... EXOSC8 mutations alter mRNA metabolism and cause hypomyelination with spinal muscular atrophy and cerebellar hypoplasia.

11 Jun 2018: Absence of p53 in cells makes them more likely to become tumorous as damage can no longer be corrected. ... While this might also decrease the risk of selecting for p53-deficient cells, it could leave cells temporarily vulnerable to mutations that cause

2 Jun 2024: RPE-1) cell line activate p53, causing cell growth arrest and DNA repair via the NHEJ pathway. ... A delicate balance is required, however, as p53 inhibition can leave cells vulnerable to tumorigenic mutations.